ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer
ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data at...